Like most genes you get 1 from mum, and 1 from dad.
You can get either a "C" or a "T" IL28 gene from each of your parents.
In the days of interferon having "CC" ie 2 copies of the "C" IL28 gene improved your chances of SVR. Two copies of the "T" ie "TT" predicted you would probably fail. As you might expect "CT" or "TC" ie one "C" and one "T" from your parents put you in the middle.
With DAAs it's not really important because TT, CT and CC people all do well. It's probably still a little advantageous to have "CC" but there is little point in testing for this these days, and after all, there is nothing you can do about it.
I was wondering about this the other day when you posted the new Decision Support Tool.
i.e. For genotypes 2/4/5/6 is there any advantage when making a decision on treatment for the new Australian guidelines that recommend Peg/Riba with Sofosbuvir? Eg "if the patient has TT and maybe CT then follow EASL guidelines and prescribe Sof/Dac"
Or would using Sof with the Peg/Riba negate any advantage there?
G3a since '78 - Dx '12 - F4 (2xHCC)
24wk Tx - PEG/Riba/Dac 2013 relapsed
24wk Tx - Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx - 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 - 22/06/17 UND
SRV12 - 27/07/17 UND
SVR24 - 26/10/17 UND
Ah yes and after the tx failed me and popped me into hospital and so on they did my Il28 and I was CT
Thanks to the FixHepC people for my Sof/Led it's changed my life and I haven't even had my first bloods done yet. You have given this liver clinic bench warmer hope and a brighter future
Peg/inf/riba 2012(!) stop @ Wk 43 potassium low +issues (rlps week 4 post tx, VL120,000) scnds eg. adenomas.
pre sof/led VL 240,000 Fibsc F0
Day 25 <30
Day 32 UND
Week 10 UND
EOT UND ALT11AST17GGT19
SVR4 UND ALT10 AST16 GGT13
SVR8 UND ALT <9 AST16 GGT15
SVR12 UND ALT14 AST19 GGT12 Bili 5
EOT +18 ALT13 AST20 GGT9 Bili 5
EOT +21 ALT11AST15
Dysplasia Adenomas RemvdAug '16
SVR24 UND ALT11AST16